arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

BioScience Health Innovations, Inc.

BHIC

— Price unavailable

7 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Good

Bullish

auto_awesome

Analytical Summary

BioScience Health Innovations, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —

Dividend Yield —

Revenue Growth 208.3% →

Op. Margin 12.6% ↗

ROIC 38.5% ↗

FCF / Share $0.02 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$5.69M

↑ +208.3% —

Net Income Profit after all expenses

$642.09K

↑ +638.0% —

Operating Margin Operating profit as % of sales

12.6%

↑ +168.0% 62th

FCF / Share Free cash flow per share

$0.02

↑ +609.0% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Profitability

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Aug 31, 2021 10-K ↗	FY 2020 Aug 31, 2020 10-K ↗	FY 2019 Aug 31, 2019 10-K ↗
Revenue Growth YoY (%)	208.3% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1636%)	208.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1639%)	761.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+6248%)	—	—	—	—
EPS Growth YoY (%)	500.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—	—	—	—
Net Income Growth YoY (%)	638.0% Excellent ↑ Excellent Improving Year-over-year change in net income	N/M	-47.6% Weak ↑ Weak Improving Year-over-year change in net income	-565.6% Weak Weak Year-over-year change in net income	-233.4% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	609.0% Excellent Excellent Year-over-year change in free cash flow	N/M	—	—	—	—	—
Revenue CAGR 3Y (%)	334.5% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Aug 31, 2021 10-K ↗	FY 2020 Aug 31, 2020 10-K ↗	FY 2019 Aug 31, 2019 10-K ↗
Operating Margin (%) (%)	12.6% Fair ↑ Fair Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-37%)	4.7% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-76%)	-42.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-310%)	-245.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1329%)	—	—	—
Effective Tax Rate (%) (%)	—	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	11.3% Fair ↑ Fair Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-25%)	4.7% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-69%)	-42.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-381%)	-245.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1739%)	—	—	—
FCF Margin (%) (%)	3.0% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	1.3% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-51.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-263.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.27x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.27x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.22x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Aug 31, 2021 10-K ↗	FY 2020 Aug 31, 2020 10-K ↗	FY 2019 Aug 31, 2019 10-K ↗
Return on Invested Capital (%)	38.5% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	8.2% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	2939.1% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	783.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	200.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-47.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	42.1% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	10.0% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	-269.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-539.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-405.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-37.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	43.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+135%)	10.4% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-44%)	—	—	200.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+982%)	-59.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-424%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Aug 31, 2021 10-K ↗	FY 2020 Aug 31, 2020 10-K ↗	FY 2019 Aug 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	-56.91x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-661.92K	$-662.52K	$-19.24K	$-11.57K	—	$-20.63K	$0.00

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Aug 31, 2021 10-K ↗	FY 2020 Aug 31, 2020 10-K ↗	FY 2019 Aug 31, 2019 10-K ↗
Revenue per Share (USD)	$0.52	$0.18	$0.02	—	—	—	—
Basic EPS, GAAP (USD)	$0.06	$0.01	$-0.01	—	—	—	—
Free Cash Flow per Share (USD)	$0.02	$0.00	$-0.01	—	—	—	—
Book Value per Share (USD)	$0.13	$0.08	$-0.00	$-0.00	$-0.00	$0.00	$0.00
Tangible Book Value per Share (USD)	$0.13	$0.07	$-0.00	$-0.00	$-0.00	$0.00	$0.00
Basic Weighted Avg Shares (shares)	10.98M	10.48M	33.76M	—	—	—	—

🏦 How resilient is the balance sheet? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Aug 31, 2021 10-K ↗	FY 2020 Aug 31, 2020 10-K ↗	FY 2019 Aug 31, 2019 10-K ↗
Total Equity (USD)	$1.48M	$835.24K	$-6.76K	$-17.18K	$-12.79K	$12.82K	$0.00

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Aug 31, 2021 10-K ↗	FY 2020 Aug 31, 2020 10-K ↗	FY 2019 Aug 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$5.69M	$1.84M	$597.60K	$69.34K	$0.00	$0.00	—
Net Income, GAAP (USD)	$642.09K	$87.00K	$-251.50K	$-170.45K	$-25.61K	$-7.68K	—
Operating Cash Flow (USD)	$172.18K	$23.19K	$-307.84K	$-182.78K	$-29.44K	$-7.68K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 29 quarters

BioScience Health Innovations, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BHIC with peers